|1.||Pezzuto, John M: 2 articles (01/2007 - 01/2007)|
|2.||Maiti, Arup: 1 article (01/2007)|
|3.||Croy, Vicki L: 1 article (01/2007)|
|4.||Kondratyuk, Tamara: 1 article (01/2007)|
|5.||Cuendet, Muriel: 1 article (01/2007)|
|6.||Cushman, Mark: 1 article (01/2007)|
|7.||Moriarty, Robert M: 1 article (01/2007)|
|8.||Murillo, Genoveva: 1 article (01/2007)|
|9.||Hirschelman, Wendy H: 1 article (01/2007)|
|10.||Kinghorn, A Douglas: 1 article (01/2007)|
|1.||Aberrant Crypt Foci
|2.||Colonic Neoplasms (Colon Cancer)
01/01/2007 - "The present study is the first to report the potent anticancer activity of zapotin and suggests a role for zapotin both as a chemopreventive and a chemotherapeutic agent against colon cancer."
01/01/2007 - "Zapotin treatment enhanced apoptosis in all of the colon cancer cell lines studied. "
01/01/2007 - "In the present study, we examined the effects of natural and synthetic zapotin in SW480, SW620, and HT-29 colon cancer cell lines and on the generation of aberrant crypt foci (ACF) using mice. "
|3.||Body Weight (Weight, Body)
01/01/2007 - "For the study of ACF, 5-wk-old CF-1 mice were given subcutaneous injections of azoxymethane (AOM; 10 mg/kg body weight, BW) weekly for 2 wk, and zapotin (5 or 10 mg/kg BW; 46 or 92 pmol/kg BW) or vehicle was administered intragastrically 7 days/wk. The mean number of ACF for the control group was 14.0+/-2.3, whereas the mean numbers of ACF in the zapotin-treated groups were 6.2+/-1.7 and 4.6+/-1.4 at doses of 5.0 and 10.0 mg/kg BW, respectively. "